Clinical Trial Update: A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating whether EA-230 can reduce hospital length of stay for patients with coronary artery disease undergoing coronary artery by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• EA-230 (EA-230)

Snippet

Sponsor: EBI Anti Sepsis BV | Conditions: Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG) | Phase 3 | Status: NOT_YET_RECRUITING